| Not Yet Recruiting | Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease NCT06998316 | University Hospital, Grenoble | — |
| Recruiting | Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Dise NCT06842316 | Centre Hospitalier Régional d'Orléans | — |
| Completed | Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism NCT05961267 | University Hospital, Bordeaux | — |
| Active Not Recruiting | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases NCT05879419 | University of Sao Paulo General Hospital | Phase 4 |
| Unknown | Survey About Diet in Chronic Inflammatory Rheumatic Diseases NCT05283096 | Poitiers University Hospital | — |
| Terminated | A Study of CC-99677 in Participants With Active Ankylosing Spondylitis NCT04947579 | Celgene | Phase 2 |
| Completed | Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis NCT04810715 | Afyonkarahisar Health Sciences University | — |
| Active Not Recruiting | The Relationship Between Inflammatory ARTritis and CArdiac DIseAse NCT05647577 | University Hospital, Gentofte, Copenhagen | — |
| Recruiting | Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response. NCT04731831 | Aalborg University Hospital | — |
| Withdrawn | Enhanced Clinics for Patients Diagnosed With Ankylosing Spondylitis and Psoriatic Arthritis NCT04341233 | NHS Lothian | — |
| Terminated | Novel Quantitative MRI for Axial Spondyloarthritis NCT03778515 | The Cleveland Clinic | — |
| Completed | Effects of Tai Chi in Patients With Ankylosing Spondylitis Receiving Anti-tumor Necrosis Factor Alpha Therapy NCT03807180 | Pamukkale University | N/A |
| Completed | A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spo NCT03733925 | Johnson & Johnson Private Limited | Phase 4 |
| Completed | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study NCT03662919 | Biogen | — |
| Completed | Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive NCT03561649 | University Hospital, Grenoble | N/A |
| Completed | The Effect of Mobile Application on Subcutaneous Anti-TNF Drug Administration:Ankylosing Spondylitis Patients NCT04301128 | Eskisehir Osmangazi University | N/A |
| Completed | Analysis of DNA Methylation in Spondyloarthritis NCT03092583 | Centre Hospitalier Universitaire de Besancon | N/A |
| Completed | Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysi NCT03033095 | University Hospital, Grenoble | N/A |
| Unknown | A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis NCT02809781 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 / Phase 3 |
| Completed | Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA NCT02509026 | Pfizer | Phase 4 |
| Completed | Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain NCT02704845 | University of Dublin, Trinity College | — |
| Completed | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankyl NCT02159053 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvemen NCT02293681 | Janssen Research & Development, LLC | — |
| Completed | Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial NCT02374502 | University of Dublin, Trinity College | N/A |
| Withdrawn | Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) NCT01870284 | Eli Lilly and Company | Phase 3 |
| Completed | Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis NCT02098694 | Norwegian University of Science and Technology | N/A |
| Completed | 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis NCT02008916 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Extension in AS: Sustainability of Benefits, Safety and Tolerability NCT01863732 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis NCT01901627 | Peking Union Medical College Hospital | — |
| Completed | Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis NCT03880968 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) NCT01453725 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Natural History and Development of Spondyloarthritis NCT01422694 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammato NCT01258738 | Pfizer | Phase 3 |
| Terminated | A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate NCT01209689 | Hoffmann-La Roche | Phase 3 |
| Completed | A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) NCT01208207 | Organon and Co | Phase 3 |
| Terminated | A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment W NCT01209702 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Ar NCT01313858 | Merck Sharp & Dohme LLC | — |
| Completed | Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects NCT01567878 | University of Sao Paulo | — |
| Terminated | An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participa NCT00766402 | Johnson & Johnson Taiwan Ltd | Phase 4 |
| Completed | A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis NCT00764686 | University College Dublin | Phase 3 |
| Completed | Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis NCT01188655 | Pfizer | — |
| Unknown | Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker NCT01072058 | University of Sao Paulo | Phase 4 |
| Terminated | Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440) NCT00686894 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Stud NCT02915354 | Sun Yat-sen University | Phase 4 |
| Completed | An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arth NCT00760669 | Janssen Korea, Ltd., Korea | — |
| Completed | C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France NCT02886689 | Central Hospital, Nancy, France | — |
| Unknown | Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondylo NCT00328068 | Charite University, Berlin, Germany | — |
| Terminated | Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthri NCT00273858 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Withdrawn | Methotrexate in the Treatment of Axial Spondyloarthritis NCT00298012 | Rheumatism Foundation Hospital | Phase 4 |
| Completed | Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) NCT00727298 | Merck Sharp & Dohme LLC | — |
| Completed | A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis NCT00265083 | Centocor, Inc. | Phase 3 |
| Completed | Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab T NCT00778869 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) NCT00202865 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P0404 NCT00779935 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04 NCT00779012 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETE NCT00725543 | Merck Sharp & Dohme LLC | — |
| Completed | Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED) NCT00818168 | Merck Sharp & Dohme LLC | — |
| Completed | Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis NCT00648141 | Pfizer | Phase 3 |
| Completed | Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to I NCT02183168 | Boehringer Ingelheim | Phase 3 |
| Completed | Blocking Tumor Necrosis Factor in Ankylosing Spondylitis NCT00000433 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |